Sentinel lymph node biopsy feasibility study in patients with primary cutaneous melanoma

Submission date	Recruitment status	 Prospectively registered
01/10/2004	No longer recruiting	Protocol
Registration date	Overall study status	Statistical analysis plan
10/01/2005 Last Edited	Completed Condition category	Results
		Individual participant data
26/04/2018	Cancer	Record updated in last year

Plain English summary of protocol

http://cancerhelp.cancerresearchuk.org/trials/a-study-to-investigate-the-diagnosis-and-treatment-of-melanoma-skin-cancer-with-sentinel-lymph-node-biopsy

Study website

http://www.icr.ac.uk/research/research_sections/clinical_trials/trials/2381_disease.shtml#

Contact information

Type(s)

Scientific

Contact name

Dr Tim Eisen

Contact details

Department of Medicine Royal Marsden Hospital Downs Road Sutton United Kingdom SM2 5PT +44 1223 40 41 91 tim.eisen@icr.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

Study information

Scientific Title

Sentinel lymph node biopsy feasibility study in patients with primary cutaneous melanoma

Acronym

SLNB

Study objectives

To compare the overall and disease-free survival in patients with a positive lymph node at biopsy.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Hospital

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Melanoma

Interventions

Completion lymphadenectomy versus no surgery

Intervention Type

Other

Phase

Phase II/III

Primary outcome measure

Not provided at time of registration

Secondary outcome measures

Not provided at time of registration

Overall study start date

01/09/2002

Completion date

13/10/2006

Eligibility

Key inclusion criteria

- 1. Patients must have clinical stage I or II invasive cutaneous melanoma with Breslow thickness greater than 1.0 mm and be suitable for lymphadenectomy surgery
- 2. The primary site must be on the trunk, limbs or digits. Patients with a primary melanoma involving the ear, eye or mucous membranes are not eligible.
- 3. Primary excision must have been within 90 days prior to the initial clinic visit
- 4. Subjects must be at least 18 years old
- 5. Karnovsky performance status greater than 70%
- 6. Women of childbearing age must have a negative pregnancy test
- 7. Subjects must voluntarily sign an informed consent form before study entry and agree to complete follow-up assessments
- 8. Adequate bone marrow, renal and hepatic function

Participant type(s)

Patient

Age group

Adult

Lower age limit

18 Years

Sex

Both

Target number of participants

120

Key exclusion criteria

- 1. Wide local excision of the primary tumour with greater than 1 cm excision margins before SLNB. Patients may have SLNB and still be eligible for excision margin studies after SLNB.
- 2. Clinical evidence of satellite, in-transit, regional nodal or distant metastases
- 3. A second primary invasive melanoma
- 4. Any malignancy in the past 5 years, except squamous cell carcinoma of the skin, basal cell carcinoma, in situ carcinoma of the uterine cervix, or Stage I laryngeal carcinoma
- 5. Prior surgery in the region of the primary draining nodal basin that would disrupt normal

lymphatic drainage patterns

- 6. Previous chemotherapy, immunotherapy or radiation therapy
- 7. Pregnancy or breast feeding
- 8. Known hypersensitivity to 99mTc-nanocolloid or patent blue dye.
- 9. History of any severe medical condition that is a significant risk to the participant leading to a life expectancy of less than 10 years prior to diagnosis of melanoma

Date of first enrolment

01/09/2002

Date of final enrolment

13/10/2006

Locations

Countries of recruitment

England

United Kingdom

Study participating centre Royal Marsden Hospital

Sutton United Kingdom SM2 5PT

Sponsor information

Organisation

Sponsor not defined - Record supplied by Institute of Cancer Research

Sponsor details

Institute of Cancer Research 123 Old Brompton Road London United Kingdom SW7 3RP

Sponsor type

Not defined

Funder(s)

Funder type

Charity

Funder Name

Cancer Research UK (CRUK) (UK)

Alternative Name(s)

CR_UK, Cancer Research UK - London, CRUK

Funding Body Type

Private sector organisation

Funding Body Subtype

Other non-profit organizations

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration